We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Diabetic Screening Performed in Dental Setting

By LabMedica International staff writers
Posted on 01 Mar 2012
Oral blood samples drawn from deep pockets of periodontal inflammation can be used to measure glycated hemoglobin (HbA1c) an important gauge of a patient's diabetes status. More...


HbA1c is widely used to test for diabetes and blood glucose measured from oral blood compare well to those from finger-stick blood where an HbA1c reading of 6.5% or more indicates a value in the diabetic range.

At the New York University (NY, USA) a nursing and dental team of scientists compared HbA1c levels in paired samples of oral gingival crevicular blood (GCB) and finger-stick blood (FSB) taken from patients with periodontal disease. The oral blood was from patients with adequate bleeding on probing and was collected on special blood collection cards.

The blood samples were analyzed for HbA1c using the BioRad Variant II Analyzer (BioRad; Hercules, CA, USA), which employs high-performance liquid chromatography, and exclusively uses BioRad Reagents. A total of 120 individuals were eligible and participated in the study and provided a FSB sample for HbA1c testing. Average FSB HbA1c readings were 6.0% ± 0.83% with 20 in the diabetes range. An additional 66 patients had FSB HbA1c test results in the prediabetes range, which is between 5.7% and 6.4%, and are at increased risk of developing diabetes in the future.

Oral blood samples were also collected from 102 of the 120 participants; no bleeding on probing or insufficient bleeding to cover adequately the tip of the blood collection wand prevented collection and/or laboratory analysis of GCB samples from the remaining 18 participants. In the case of 27 of the 102 GCB samples, an unidentified component was observed to co-elute within the elution window of HbA1c in the laboratory. The presence of a co-elution peak from this unidentified component interfered with the quantification of HbA1c and generally resulted in underestimation of true HbA1c percentages. Therefore, only 75 patients' blood samples could be compared with both tests.

Of these 75 participants, 15 had FSB HbA1c values in the diabetes range of equal to or greater than 6.5%, including 8 who indicated that they had never been told by a health care provider that they had diabetes. For these 75 participants, the correlation between FSB and GCB HbA1c values was very high. Sheila M. Strauss, PhD, the principal author said, "In light of these findings, the dental visit could be a useful opportunity to conduct an initial diabetes screening, an important first step in identifying those patients who need further testing to determine their diabetes status". The study was published online on November 16, 2011 in the Journal of Periodontology.

Related Links:

New York University
BioRad



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
HPV Test
Allplex HPV28 Detection
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image

FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing

Urinary tract infections are among the most common bacterial infections and a major driver of antibiotic prescribing, yet culture-based workflows can take days to produce results. Treatment often begins... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.